investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
CAMBRIDGE, Mass. and BAGSVÆRD, Denmark --(BUSINESS WIRE)--Oct. 9, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases,Read more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed William R. Sellers , M.D. to its Board of Directors. “I’m excited to welcome Bill to the Board to help navigate an important stage in bluebird’s evolution,” said NickRead more
Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- bluebird bio, Inc.Read more